Neuraxis (NRXS) Income towards Parent Company (2022 - 2025)
Neuraxis (NRXS) posted Income towards Parent Company of -$1.7 million for Q4 2025, up 20.96% sequentially from -$2.1 million in Q3 2025, and down 26.71% YoY from -$2.3 million in Q4 2024.
Neuraxis (NRXS) Income towards Parent Company (2022 - 2025) Analysis & Trends
Neuraxis has reported Income towards Parent Company for 4 years, with the latest figure at -$1.7 million in Q4 2025.
- Quarterly Income towards Parent Company fell 26.71% year-over-year to -$1.7 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$5.9 million (up 27.32% YoY) and the FY2025 annual result came in at -$8.2 million, down 5.87% from the prior year.
- Income towards Parent Company climbed to -$1.7 million in Q4 2025 per NRXS's latest filing, from -$2.1 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at -$704032.0 in Q2 2022 and troughed at -$3.1 million in Q3 2023.
- A 4-year average of -$1.7 million and a median of -$1.7 million in 2025 frame the typical range for Income towards Parent Company.
- The sharpest annual moves came in 2023 and 2024: Income towards Parent Company tumbled 139.51% in 2023, then jumped 45.05% in 2024.
- Over 4 years, Income towards Parent Company stood at -$1.0 million in 2022, then plunged by 58.07% to -$1.6 million in 2023, then increased by 18.22% to -$1.3 million in 2024, then slipped by 26.71% to -$1.7 million in 2025.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$1.7 million, -$2.1 million, and -$2.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Neuraxis | 75.51 Mn | 67.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.68 Mn |
| Sep 30, 2025 | -2.13 Mn |
| Jun 30, 2025 | -2.09 Mn |
| Mar 31, 2025 | -2.30 Mn |
| Dec 31, 2024 | -1.33 Mn |
| Sep 30, 2024 | -1.72 Mn |
| Jun 30, 2024 | -2.78 Mn |
| Mar 31, 2024 | -1.86 Mn |
| Dec 31, 2023 | -1.62 Mn |
| Sep 30, 2023 | -3.12 Mn |
| Jun 30, 2023 | -1.31 Mn |
| Mar 31, 2023 | -1.06 Mn |
| Dec 31, 2022 | -1.03 Mn |
| Sep 30, 2022 | -1.30 Mn |
| Jun 30, 2022 | -704,032.00 |